PSYCHOPHARMACOLOGICAL DRUGS ADVISORY COMMITTEE
November 3, 1999
Food and Drug Administration
Thomas Laughren, MD
Eli Lilly and Company
The statements contained in this document are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.
Fluoxetine in the Treatment of PMDD, Gregory T. Brophy PhD